Lupus is an autoimmune condition in which the body’s immune system mistakenly attacks its own cells and tissues. One type of lupus is drug-induced lupus (DIL), which happens when certain medications trigger this immune response. The body reacts as if it is under attack, leading to symptoms similar to those seen in systemic lupus erythematosus (SLE).
Over 38 medications have been linked to DIL, but hydralazine, procainamide, and quinidine are reported to cause the most cases. People with DIL often experience muscle aches, joint pain, fatigue, and sometimes fever. The good news is that these symptoms usually improve or disappear after stopping the medication that caused them.
Who Gets Drug-Induced Lupus Erythematosus?
Drug-induced lupus (DIL) is different from regular, idiopathic lupus (LE) in several ways.
Age
- DIL mostly affects older adults, with the average age being about twice that of idiopathic LE.
- Idiopathic LE mainly affects people in their childbearing years.
- The higher age in DIL is linked to increased medication use.
Gender
- DIL does not show a strong female predominance.
- In idiopathic LE, about 90% of cases are female.
Skin Type
- DIL is more common in people with white skin.
- Idiopathic LE is more common in people with black skin.
Relationship with Medication
- Symptoms of DIL begin after starting a causative drug.
- The time between starting the medication and the first symptoms can range from 1 month to more than 10 years.
- This delay can make it difficult to identify the drug responsible.
Genetic Factors
Some people are more prone to developing DIL due to genetic factors:
- Slow acetylator status: Medications are broken down more slowly by the liver.
- Complement C4 null allele: A protein abnormality affecting the immune system.
- Certain HLA tissue types: DR4, DR2, DR3, DR0301, DQB1, B8, 1.
Prevalence
- About 10% of systemic lupus cases may be drug-induced.
- In one case series, 20% of biopsy-confirmed subacute cutaneous LE cases were caused by medications.
Signs and Symptoms
Drug-induced lupus erythematosus (DIL) usually develops after long-term use of certain medications rather than short-term side effects. Its symptoms often resemble those of systemic lupus erythematosus (SLE), but they are generally milder. Common signs and symptoms include:
- Fatigue and general discomfort
- Serositis, which refers to inflammation of the tissues surrounding the heart and lungs
Although DIL symptoms are typically less severe than SLE, ignoring them can lead to worsening complications and, in rare cases, serious outcomes.
Causes of Drug-Induced Lupus Erythematosus
The exact cause of drug-induced lupus (DIL) is still not fully understood, even after many years of research. Scientists believe it happens due to a mix of genetics, how the body processes drugs, and immune system reactions.
Role of Acetylation Speed
- Our bodies use an enzyme called N-acetyltransferase to break down certain drugs.
- Some people have a genetic deficiency that makes them "slow acetylators," meaning their bodies process drugs more slowly.
- Studies have shown that almost all patients with DIL are slow acetylators.
- This slow breakdown leads to a buildup of drug byproducts (metabolites) in the body.
How the Immune System Reacts
- In slow acetylators, drugs like hydralazine break down into reactive substances.
- These substances combine with proteins in the body, creating new antigens.
- White blood cells detect these antigens and signal the immune system to attack, producing antinuclear antibodies (ANAs).
- This mistaken attack on the body’s own tissues causes lupus-like symptoms.
Drugs Most Commonly Linked to DIL
Some drugs carry a higher risk of causing drug-induced lupus than others.
High Risk
- Drugs for irregular heartbeats (Procainamide)
- Drugs for high blood pressure (Hydralazine)
- About 5% of patients taking high doses over a long period may develop DIL.
Moderate Risk
- Drugs for irregular heartbeats (Quinidine)
Low to Very Low Risk
- Anti–TNF-α drugs for autoimmune diseases (Infliximab, Etanercept)
- Antibiotics (Isoniazid, Minocycline, Pyrazinamide)
- Anti-inflammatory (D-Penicillamine)
- Anticonvulsants (Carbamazepine, Oxcarbazepine, Phenytoin)
- Antiarrhythmic (Propafenone)
- Antipsychotic (Chlorpromazine)
- Drugs for high blood pressure, also used for hair growth (Minoxidil)
How is Drug-Induced Lupus Erythematosus Diagnosed?
Diagnosing drug-induced lupus erythematosus (DIL) can be challenging because its symptoms are very similar to those of systemic lupus erythematosus (SLE). However, there are a few key points that help doctors identify it.
When to Suspect DIL
- If an older person develops lupus-like symptoms, especially subacute cutaneous lupus on the legs, doctors may consider DIL.
- Unlike idiopathic lupus, DIL usually appears after starting a certain medication.
- Symptoms typically improve after the drug is stopped.
Diagnostic Criteria
There are no official standard criteria for diagnosing DIL. Most patients do not meet the full American Rheumatologic Association (ARA) criteria for SLE.
However, the proposed criteria include:
- At least one clinical symptom of lupus (such as joint pain, rash, or fatigue).
- A positive ANA test and other lupus-related blood tests.
- Clear time relationship with starting the drug.
- Resolution of symptoms when the drug is stopped.
Blood Test Findings
Drug-Induced Systemic Lupus (SLE)
- ANA (antinuclear antibodies): Positive in up to 90%, usually with a homogeneous pattern.
- Anti-histone antibodies: Positive in 75–95% (only ~20% in idiopathic SLE).
- Anti-dsDNA and ENA: Rarely positive (<5%).
- ESR (inflammation marker): May be high.
- Blood cells: Mild decrease in red cells, white cells, or platelets (not severe).
- Some drugs show specific antibody patterns (e.g., quinidine and antiphospholipid antibodies).
Drug-Induced Subacute Cutaneous Lupus
- ANA is frequently positive.
- Anti-Ro/SSA and Anti-La/SSB antibodies are usually present.
- Anti-histone antibodies are commonly detected.
- Anti-dsDNA antibodies are typically absent.
- Blood counts are generally within the normal range.
Drug-Induced Chronic Cutaneous Lupus
- ANA is positive in about 66% of cases.
- Anti-histone antibodies are rarely found.
- ENA and anti-dsDNA antibodies are negative.
- Blood counts remain normal.
Skin Biopsy Findings
- The skin biopsy in DIL looks the same as in idiopathic lupus.
- Both histology and direct immunofluorescence show no difference between the two.
{{lupus-cta-banner}}
Treatment and Management of Drug-Induced Lupus
The good news is that drug-induced lupus (DIL) usually improves once the causative drug is stopped. Treatment mainly focuses on relieving symptoms and monitoring recovery.
1. Stop the Offending Drug
- The first and most important step is to immediately discontinue the medication causing the reaction.
- Symptoms often start to fade within weeks to months after stopping the drug.
2. Symptom Relief
Depending on the severity of symptoms, treatment may include:
- NSAIDs (Nonsteroidal Anti-Inflammatory Drugs): To reduce joint pain and inflammation.
- Corticosteroids: For more severe or persistent symptoms such as widespread inflammation or organ involvement.
3. Monitoring Recovery
- Patients are closely monitored until symptoms resolve.
- Most people recover fully, though in rare cases, it may take several months for the immune system to settle.
Other Types of Lupus
Lupus appears in several forms, each affecting the body differently, with some limited to the skin and others involving internal organs. These include:
Clinical Trials Shaping the Future of Skin Treatments
Dermatology Clinical Research Studies play a vital role in understanding and improving treatments for skin conditions. These studies explore new therapies, assess their safety, and measure effectiveness, giving patients access to innovative care options. By participating, individuals contribute to advancements that can enhance skin health and overall quality of life.
Indiana University is conducting Cutaneous Lupus Clinical Trials focused on finding better treatments for lupus that affects the skin. Joining this trial not only gives patients potential access to advanced therapies but also allows them to contribute to the progress of lupus research.
{{lupus-cta-banner}}
Conclusion:
In conclusion, drug-induced lupus is a manageable condition that arises from long-term use of certain medications. Recognizing symptoms early and stopping the offending drug are key to recovery. With proper diagnosis, treatment, and monitoring, most patients experience complete symptom resolution and can return to living healthy, active lives. Moreover, Clinical Research Studies in Indiana are conducting trials to explore potential new options for various skin conditions.
